Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms Post author: Post published: November 22, 2023 Post category:uncategorized Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19. You Might Also Like Plastic chemicals linked to nearly two million premature births March 31, 2026 New map offers valuable insights into the underlying mechanisms of neurodevelopmental disorders and cancer December 11, 2023 The effect of supplementation with cornelian cherry on different cardiometabolic outcomes July 11, 2024
New map offers valuable insights into the underlying mechanisms of neurodevelopmental disorders and cancer December 11, 2023
The effect of supplementation with cornelian cherry on different cardiometabolic outcomes July 11, 2024